Amarin (AMRN) Sees Upside After AstraZeneca Scoops-Up Omthera (OMTH)
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Amarin Corp Plc (NASDAQ: AMRN) is seeing pre-open interest Tuesday after AstraZeneca (NYSE: AZN) acquired fellow fish oil pharmaceutical company Omthera Pharmaceuticals (NASDAQ: OMTH) for as much as $443 million.
While the comparable valuation of the deal is not viewed as positive for Amarin, speculators suggest the deal activity puts the spotlight directly on Amarin.
Shares of Amarin last traded at $7.05, up 4 percent.
While the comparable valuation of the deal is not viewed as positive for Amarin, speculators suggest the deal activity puts the spotlight directly on Amarin.
Shares of Amarin last traded at $7.05, up 4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackstone (BX) Nears Deal to Sell Control of S.Korean Pharma Wholesaler Geo-young to MBK Parnters for Over $1B - Reuters
- United Airlines to Defer Some New Planes Due to US Safety Review - Bloomberg
- Tesla (TSLA) continues to slide, breaks under $150
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
